Brief: Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer
17/04/2026 21:46
April 17 (Reuters) - Agenus Inc AGEN.O: AGENUS REPORTS PHASE II DATA DEMONSTRATING IMMUNE REPROGRAMMING AND DURABLE SURVIVAL WITH BOTENSILIMAB, BALSTILIMAB AND AGENT-797 IN PD-1 REFRACTORY GASTROESOPHAGEAL CANCER AGENUS INC - STUDY DOES NOT MEET PRIMARY ENDPOINT OF OBJECTIVE RESPONSE RATE Source text: ID:nBwbVdvpHa Further company coverage: AGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income